Looking at surging obesity drug sales, market share momentum, and an increased fair value estimate, here’s what we think of ...

Two new RCTs of rituximab will soon begin in the United Kingdom: A biomarker-based trial with add-on belimumab and another in ...

Sales are booming for Lilly's tirzepatide products, Mounjaro and Zepbound. The company's market share for incretin analogs now tops 50%. Notably, Lilly's market share is increasing while Novo ...

Patrick Holden, 29, was a rising star in the world of pharmaceutical medicine and had just started a new life in New York ...

A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...

A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...

Chief Scientific Officer Dr. Daniel Skovronsky talked with the IBJ about his hopes for the Lilly Medicine Foundry, which the ...

The Food and Drug Administration should look for ways to streamline regulations on new U.S. drug manufacturing facilities to ...

GLP-1 receptor agonists remain blockbuster drugs for weight management for people with overweight or obesity. Increasingly, ...

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an ...